Please login to the form below

Not currently logged in
Email:
Password:

erenumab

This page shows the latest erenumab news and features for those working in and with pharma, biotech and healthcare.

NICE delivers final ‘no’ for Novartis’ migraine treatment Aimovig

NICE delivers final ‘no’ for Novartis’ migraine treatment Aimovig

Blow to patients who have dubbed the treatment 'life-saving'. Novartis has been delivered another ‘no’ for its migraine prevention drug Aimovig (erenumab) from NICE, following draft guidance which rejected the

Latest news

More from news
Approximately 1 fully matching, plus 22 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics